HONG KONG, Dec. 16, 2024 /PRNewswire/ -- The 2024 Academy of International Business (AIB) Asia Pacific Regional Conference was held from 4 to 6 December in Guangzhou. This year's conference, "Reimagine International Business: Accelerate Growth through Collaboration and Digital Transformation", attracted nearly 200 experts and scholars from around the world to discuss the latest trends and challenges in the field of international business. Prof Bradley R. Barnes, President of the AIB Asia Pacific Chapter, and Interim Associate Vice-President (Global Affairs) cum Director of Global Education at Lingnan University, chaired the conference, and Prof Cui Geng, Executive Director of AIB Asia Pacific Chapter, Professor of the Department of Marketing and International Business of Lingnan University, hosted the event at the Guangdong University of Foreign Studies (GDUFS), where he is currently on a two year sabbatical.
Prof Sebastian Chung Yu-ho, Assistant Professor of the Department of Marketing and International Business at Lingnan University spoke in a special plenary session relating to Hong Kong-Mainland Economic Integration. Panellists were from the Education University of Hong Kong, the Guangdong University of Foreign Studies, and the Zowoyoo Group, and they shared perspectives on the significance and progress of the integration of Hong Kong and the Mainland over the past few years, particularly since the announcement of the Greater Bay Area strategic initiative and following the pandemic. The panellists noted that while COVID-19 disrupted supply chains and economic activities, it also accelerated digital transformation, highlighting the importance of regional cooperation. The GBA initiative presents a unique opportunity to enhance Hong Kong's role as a gateway to Mainland China, they agreed, but it necessitates careful management to maintain its distinctive advantages.
Professors from Lingnan University presented their work on a Hong Kong-Mainland Economic Integration Index, and shared insights and perspectives in Q&A discussions. Booklets detailing the economic index were distributed to all attendees, who included industry professionals and academics, highlighting the pivotal developments in economic integration between Hong Kong and the Mainland over the past four decades.
The conference was an excellent opportunity for Lingnan to engage with leading experts and contribute to meaningful discussions on the future of international business.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Lingnan University participates in the 2024 Academy of International Business Asia Pacific Regional Conference
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio™AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support.
The 1Bio™AI-Acute system uses only bedside-recorded vital signs—pulse rate, respiratory rate, oxygen saturation, and systolic blood pressure—to generate a probability score that assists clinicians in determining whether additional monitoring may be required. This score provides an indication of the patient's general physiological state: the higher the score, the greater the likelihood that the patient may require additional monitoring due to potential acute deterioration.
WHY IT MATTERS
"Current early-warning scores that rely on threshold-based methods often suffer from low precision, leading to a high number of alarms and notifications. Advanced AI-driven machine learning models have the potential to deliver significantly greater precision, reducing unnecessary alerts/notifications, thus enabling healthcare professionals to better focus their time on delivering quality patient care," said Dr. Gurpreet Singh, CEO and Founder of Respiree.
The 1Bio™AI-Acute is readily available to healthcare professionals through Respiree's 1Bio™ platform, which recently received regulatory clearance together with the RS001 wearable device. With this milestone, the 1Bio™AI-Acute toolbox, the 1Bio™platform, and the RS001 wearable are all now approved by HSA.
With the HSA approval for the 1Bio™AI-Acute toolbox, Respiree is now setting its sights on expanding the 1Bio™AI-Acute regulatory approvals across other APAC and ANZ regions, as well as in the United States, in the coming months.
HSA's approval of the 1Bio™AI-Acute toolbox follows the validation study that was recently peer-reviewed and published in the Mayo Clinic Proceedings.
About Respiree
Respiree™ is an AI/ML health tech company building clinically-validated AI for managing disease progression. Respiree™ products are CE marked and has received regulatory clearances from the Therapeutic Goods Administration and the United States Food and Drug Administration (FDA).
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION
